Top Analyst Upgrades and Downgrades: Abbott Labs, CenterPoint, Dominion, Delphi, Disney, Dollar General, Lennar, Lululemon, Visa, Zillow and More

Print Email

Stocks were indicated to open higher on Thursday morning after two days of small losses in the major equity indexes. With so many nontraditional developments and so many sidebar issues affecting the markets and the economy, investors have to be considering how they want their portfolios and assets positioned for the summer and into late 2019.

24/7 Wall St. reviews dozens of analyst research reports each day of the week in an effort to find new ideas for traders and long-term investors alike. Some of the daily analyst calls cover stocks to buy. Other analyst calls cover stocks to sell or to avoid.

We have provided these calls in a quick-hit summary for easy reading and additional comments and trading data have been added on some of the calls. The consensus analyst price targets and other valuation metrics are from the Refinitiv (Thomson Reuters) sell-side research service.

These are the top analyst upgrades, downgrades and initiations on Thursday, June 13, 2019.

Abbott Laboratories (NYSE: ABT) was reiterated as Outperform and the target price was raised to $91 from $89 at Wells Fargo. Shares closed up 1% at $81.95, in a 52-week range of $60.32 to $82.00 and with a consensus target price of $83.06.

Atlassian Corp. PLC (NASDAQ: TEAM) was reiterated as Overweight and the target price was raised to $142 from $121 at KeyBanc Capital Markets.

CenterPoint Energy Inc. (NYSE: CNP) was raised to Buy from Neutral at Merrill Lynch.

Dominion Energy Inc. (NYSE: D) was raised to Neutral from Underperform at Merrill Lynch.

Concert Pharmaceuticals Inc. (NASDAQ: CNCE) was raised to Buy from Neutral and the fair value was raised to $16 from $14 at Janney. The upgrade was based on the company announcing positive Phase 1 SAD/MAD data of CTP-692 (deuterated D-serine) as an adjunctive treatment to antipsychotics for schizophrenia and that it was well-tolerated with no signs of renal toxicity.

CytomX Therapeutics Inc. (NASDAQ: CTMX) was started as Buy and assigned a $16 target price at Mizuho.

Delphi Technologies PLC (NYSE: DLPH) was raised to Buy from Neutral and the price target was lowered to $24 from $25 at Goldman Sachs.

Dollar General Corp. (NYSE: DG) was reiterated as Outperform and as a Top Pick at Oppenheimer, but the firm raised its target price to $150 from $135 in the call. Shares closed up 0.4% at $136.04, in a 52-week range of $95.61 to $136.43 and with a consensus target price of $136.68.

Lennar Corp. (NYSE: LEN) was raised to Outperform from Neutral and the price target was raised to $62 from $50 at Wedbush Securities. The call noted mortgage rates near two-year lows, housing sectors rebounding and continuing demand for affordable housing by multiple demographic groups as reasons why investors should be willing to pay a higher multiple for homebuilder earnings.

Lululemon Athletica Inc. (NASDAQ: LULU) closed down 0.4% at $170.89 ahead of earnings and initially traded up by 2% in the after-hours session on Wednesday, and it was indicated up over 4% at $178.20 on Thursday morning after the quarterly report. Morgan Stanley maintained it at Equal Weight but raised the price target to $163 from $160. RBC Capital Markets raised its target price to $200 from $190.

Lyft Inc. (NASDAQ: LYFT) was started as Outperform and assigned a $75 price target at Evercore ISI. Shares closed up 0.6% at $58.41, in a post-IPO range of $47.17 to $88.60 and with a consensus target price of $72.79.